相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands
R. Mould et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Molecular determinants of drug-receptor binding kinetics
Albert C. Pan et al.
DRUG DISCOVERY TODAY (2013)
Pharmacokinetics and the drug-target residence time concept
Goran Dahl et al.
DRUG DISCOVERY TODAY (2013)
Structure-Kinetic Relationships-An Overlooked Parameter in Hit-to-Lead Optimization: A Case of Cyclopentylamines as Chemokine Receptor 2 Antagonists
Maris Vilums et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Molecular Basis for the Long Duration of Action and Kinetic Selectivity of Tiotropium for the Muscarinic M3 Receptor
Christofer S. Tautermann et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structure of class B GPCR corticotropin-releasing factor receptor 1
Kaspar Hollenstein et al.
NATURE (2013)
Dual-Point Competition Association Assay: A Fast and High-Throughput Kinetic Screening Method for Assessing Ligand-Receptor Binding Kinetics
Dong Guo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics
Rogier A. Smits et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time
Dong Guo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Target-drug interactions: first principles and their application to drug discovery
Sara Nunez et al.
DRUG DISCOVERY TODAY (2012)
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D2 receptor antagonist in the treatment of acute exacerbation of schizophrenia
Mark E. Schmidt et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
Paul W. Jones et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
An update of novel screening methods for GPCR in drug discovery
Linjie Chen et al.
EXPERT OPINION ON DRUG DISCOVERY (2012)
Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release
Lucia Carboni et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design
Miles Congreve et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Structure and dynamics of the M3 muscarinic acetylcholine receptor
Andrew C. Kruse et al.
NATURE (2012)
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism
Georges Vauquelin et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
D2-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D2-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection
Mark E. Schmidt et al.
PSYCHOPHARMACOLOGY (2012)
A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients
D. Singh et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2012)
Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target
Duncan C. Miller et al.
MEDCHEMCOMM (2012)
The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
Francois Maltais et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2012)
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease
Vandana Gupta et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2012)
The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium
David A. Sykes et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Pharmacology of JNJ-37822681, a Specific and Fast-Dissociating D2 Antagonist for the Treatment of Schizophrenia
Xavier Langlois et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor
Beth A. Fleck et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Molecular properties affecting fast dissociation from the D2 receptor
Gary Tresadern et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Sodium [2′-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4′-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): A potent, selective prostaglandin D2 receptor antagonist
Nicholas Stock et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles
Duncan C. Miller et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK1 and NK3 receptors
P. Malherbe et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo
Simeon J. Ramsey et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors
R. J. Slack et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Conformational adaptation in drug-target interactions and residence time
Robert A. Copeland
FUTURE MEDICINAL CHEMISTRY (2011)
Biophysical Mapping of the Adenosine A2A Receptor
Andrei Zhukov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery and Biological Characterization of (2R,4S)-1′-Acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4′-bipiperidine-1-carboxamide as a New Potent and Selective Neurokinin 1 (NK1) Receptor Antagonist Clinical Candidate
Romano Di Fabio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Inhalation by Design: Novel Tertiary Amine Muscarinic M3 Receptor Antagonists with Slow Off-Rate Binding Kinetics for Inhaled Once-Daily Treatment of Chronic Obstructive Pulmonary Disease
Paul A. Glossop et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol
Paola Casarosa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
How were new medicines discovered?
David C. Swinney et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery
Nathan Robertson et al.
NEUROPHARMACOLOGY (2011)
Molecular obesity, potency and other addictions in drug discovery
Michael M. Hann
MEDCHEMCOMM (2011)
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
Anthony D'Urzo et al.
RESPIRATORY RESEARCH (2011)
Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor
Gregori J. Morriello et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists
Gregori J. Morriello et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach
A. Packeu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo
D. J. Behm et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Georges Vauquelin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
Nick Pantaleo et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2010)
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
M. S. Kipnes et al.
DIABETES OBESITY & METABOLISM (2010)
Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs
Rumin Zhang et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
L. J. Aronne et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Grading the commercial optical biosensor literature-Class of 2008: 'The Mighty Binders'
Rebecca L. Rich et al.
JOURNAL OF MOLECULAR RECOGNITION (2010)
Tachykinin receptor antagonists in clinical trials
Laura Quartara et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Identification of a Critical Residue in the Transmembrane Domain 2 of Tachykinin Neurokinin 3 Receptor Affecting the Dissociation Kinetics and Antagonism Mode of Osanetant (SR 142801) and Piperidine-Based Structures
Pari Malherbe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Discovery Process and Pharmacological Characterization of 2-(S)-(4-Fluoro-2-methylphenyl)piperazine-1-carboxylic Acid [1-(R)-(3,5-Bis-trifluoromethylphenyl)ethyl]methylamide (Vestipitant) as a Potent, Selective, and Orally Active NK1 Receptor Antagonist
Romano Di Fabio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Discovery of Novel Quaternary Ammonium Derivatives of (3R)-Quinuclidinol Esters as Potent and Long-Acting Muscarinic Antagonists with Potential for Minimal Systemic Exposure after Inhaled Administration: Identification of (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide (Aclidinium Bromide)
Maria Prat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Multifaceted Approach to Determine the Antagonist Molecular Mechanism and Interaction of Ibodutant ([1-(2-Phenyl-1R-{[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide) at the Human Tachykinin NK2 Receptor
Stefania Meini et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile
Amadeu Gavalda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Preclinical Evaluation of Long-Acting Muscarinic Antagonists: Comparison of Tiotropium and Investigational Drugs
Paola Casarosa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Kinetic Binding Analysis of Aptamers Targeting HIV-1 Proteins by a Combination of a Microbalance Array and Mass Spectrometry (MAMS)
Thomas M. A. Gronewold et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: Application to (R)-dimethindene occupancy of central histamine H1 receptors
Siobhan Malany et al.
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION (2009)
Exploring the Mechanism of Agonist Efficacy: A Relationship between Efficacy and Agonist Dissociation Rate at the Muscarinic M-3 Receptor
David A. Sykes et al.
MOLECULAR PHARMACOLOGY (2009)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists
Gregori J. Morriello et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
The state of innovation in drug development
I. Kola
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand
Deborra Mullins et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Partial agonism at the human α2A-autoreceptor:: role of binding duration
M. Hoeren et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
A 4-year trial of tiotropium in chronic obstructive pulmonary disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Novel P2Y(12) adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization
Joseph M. Post et al.
THROMBOSIS RESEARCH (2008)
Surface acoustic wave sensors in the bioanalytical field: Recent trends and challenges
Thomas M. A. Gronewold
ANALYTICA CHIMICA ACTA (2007)
Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists
Jonathan R. Young et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociation
Georges Vauquelin et al.
NEUROCHEMISTRY INTERNATIONAL (2007)
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - GOLD executive summary
Klaus F. Rabe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Neurokinin 1 receptor antagonists:: Correlation between in vitro receptor interaction and in vivo efficacy
Erik Lindstroem et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Pharmacological characterization of sch527123, a potent allosteric CXCR1/CXCR2 antagonist
Waldemar Gonsiorek et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Scintillation proximity assay as a high-throughput method to identify slowly dissociating nonpeptide ligand binding to the GnRH receptor
Christopher E. Heise et al.
JOURNAL OF BIOMOLECULAR SCREENING (2007)
Higher-throughput, label-free, real-time molecular interaction analysis
Rebecca L. Rich et al.
ANALYTICAL BIOCHEMISTRY (2007)
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor
Mark R. Dowling et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Opinion - How many drug targets are there?
John P. Overington et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Pooled clinical trial analysis of tiotropium safety
Steven Kesten et al.
CHEST (2006)
Determining the potency and molecular mechanism of action of insurmountable antagonists
Terry Kenakin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Can binding kinetics translate to a clinically differentiated drug? From theory to practice
David C. Swinney
LETTERS IN DRUG DESIGN & DISCOVERY (2006)
Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor
Carol Smith et al.
MOLECULAR PHARMACOLOGY (2006)
Kinetics of nonpeptide antagonist binding to the human gonadotropin-releasing hormone receptor: Implications for structure-activity relationships and insurmountable antagonism
Susan K. Sullivan et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse
Thora K. Bjarnadottir et al.
GENOMICS (2006)
Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology
Iva Navratilova et al.
ANALYTICAL BIOCHEMISTRY (2006)
Slow antagonist dissociation and long-lasting in vivo receptor protection
Georges Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004: Mechanisms leading to optimal efficacy and safety
David C. Swinney
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2006)
What has been learnt from study of dopamine receptors in Parkinson's disease?
M. J. Hurley et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics
C Chen
CURRENT MEDICINAL CHEMISTRY (2006)
The druggable genome: an update
AP Russ et al.
DRUG DISCOVERY TODAY (2005)
The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders
DE Grigoriadis
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?
DP Tashkin
CURRENT OPINION IN PULMONARY MEDICINE (2005)
Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis
P Seeman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
S Miyamoto et al.
MOLECULAR PSYCHIATRY (2005)
Tachykinins and tachykinin receptors: a growing family
JN Pennefather et al.
LIFE SCIENCES (2004)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
Tachykinins and tachykinin receptors:: Structure and activity relationships
TA Almeida et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases
A Lecci et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2003)
Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome
K Mihara et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2003)
A general method for the covalent labeling of fusion proteins with small molecules in vivo
A Keppler et al.
NATURE BIOTECHNOLOGY (2003)
Models and methods for studying insurmountable antagonism
G Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Seven-transmembrane receptors
KL Pierce et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor
JC Anthes et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
New insights in insurmountable antagonism
G Vauquelin et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2002)
Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists
RA Duffy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease
JA van Noord et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
D1 dopamine receptor:: A putative neurochemical and behavioral link to cocaine action
M Hummel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
The CRF peptide family and their receptors: yet more partners discovered
FM Dautzenberg et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Non-Peptidic CRF1 Receptor Antagonists for the Treatment of Anxiety, Depression and Stress Disorders
J. Kehne et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2002)
Gonadotropin-releasing-hormone-receptor antagonists
JAF Huirne et al.
LANCET (2001)
Insurmountable AT1 receptor antagonism:: the need for different antagonist binding states of the receptor
G Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2001)
Distinctions between non-peptide angiotensin II AT1-receptor antagonists
G Vauquelin et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2001)
Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?:: A new hypothesis
S Kapur et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
G Vauquelin et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Neurokinin(1) receptor antagonists as potential antidepressants
SC Stout et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
How can the differences among AT(1)-Receptor antagonists be explained?
P Morsing et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2001)
Transient D2 dopamine receptor occupancy in low EPS-incidence drugs:: PET evidence
C Jones et al.
BIOLOGICAL PSYCHIATRY (2000)
Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
PJ Gilligan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Low dopamine D-2 receptor binding potential in social phobia
FR Schneier et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
分享论文
